14 August 2010, MicroPort announced the kick-off of TARGET I - the pre-approval multicenter clinical trial of MicroPort's new-generation drug-eluting stent system FIREHAWK, in the Continental Beijing Beichen Hotel. The event was witnessed by dozens of renowned experts in coronary intervention as well as MicroPort's top management including CMO Philip Li Wang and CTO Qiyi Luo. Vice President of Quality and Regulatory Mr. Yimin Xu chaired the meeting.
TARGET I - the prospective randomized controlled multicenter trial in which Mr. Runlin Gao, an academician of Cardiovascular Institute and Fuwai Hospital, Peking Union Medical College and Professor Martin B. Leon of Columbia University Medical Center served as principal investigator and co-principal investigator respectively, aimed at assessing the safety, effectiveness and performance of the stent delivery system and providing more valuable information and scientific basis for marketing approval.
Privacy settings
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.
For more information, please see our Cookie Policy.